Cancer Treatment Reviews
Volume 24, Issue 2 , Pages 119-131 , April 1998

Colorectal cancer: treatment of advanced disease

References 

  1. Parker SL, Tong T, Bolden S, Wingo PA. Cancer statistics, 1996. CA Cancer J Clin. 1996;46(1):5–27
  2. Cancer Research Campaign . Cancer Statistics Factsheet 3.2–3. 1995;
  3. In:  Forman D,  Rider L editor. Cancer in Yorkshire—Cancer Statistics 1989-93. Yorkshire Cancer Organisation; 1996;
  4. Hughes KS. Resection of the liver for colorectal carcinoma metastases—a multi-institutional study of indications for resection. Surgery. 1988;103(3):278–288
  5. Steele G, Ravikumar TS. Resection of hepatic metastases from colorectal cancer. Ann Surg. 1989;210:127–138
  6. Scheele J, Stand R, Altendorfhofmann A, Paul M. Resection of colorectal liver metastases. World J Surg. 1995;19(1):59–71
  7. Adson MA. Resection of liver metastases—when is it worthwhile?. World J Cancer. 1987;11(4):511–520
  8. Rougier P, Milan C, Lazorthes F, et al.  Prospective-study of prognostic factors in patients with unresected hepatic metastases from colorectal cancer. Br J Surg. 1995;82(10):1397–1400
  9. Norstein J, Silen W. Natural history of liver metastases from colorectal carcinoma. J Gastrointest Surg. 1997;1:398–407
  10. SSAT, AGA, ASLD, ASGE, AHPBA Consensus Panel . Treatment of hepatic metastases from colorectal cancer. J Gastrointest Surg. 1997;1:396–397
  11. Slevin ML, Stubbs L, Plant HJ, et al.  Attitudes to chemotherapy: comparing the views of patients with cancer with those of doctors, nurses and the general public. Br Med J. 1990;300:1458–1460
  12. Scheithauer W, Rosen H, Komet GV, Sebesta C, Depisch D. Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer. Br Med J. 1993;306:752–755
  13. Glimelius B, Hoffman K, Graf W, et al.  Cost-effectiveness of palliative chemotherapy in advanced gastrointestinal cancer. Ann Oncol. 1995;6:267–274
  14. Beretta G, Bollina R, Cozzi C, Beretta A. Should we consider the weekly chemotherapy with fluorouracil plus racemic folinic acid a standard treatment for advanced/metastatic carcinoma of digestive tract in elderly patients?. In: 4th edition. Proc Am Soc Clin Oncol. 16:1997;p. 920
  15. Nordic Gastrointestinal Tumour Adjuvant Therapy Group. Expectancy or primary chemotherapy in patients with advanced asymptomatic colorectal cancer: a randomized trial. J Clin Oncol. 1992;10:904–911
  16. Hafstrom L, Engaras B, Holmberg SB, et al.  Treatment of liver metastases from colorectal cancer with hepatic artery occlusion, intraportal 5-fluorouracil infusion and oral allopurinol. In: A randomized clinical trial. 4th edition. Cancer. 74:1994;p. 2749–2756
  17. Rougier P, Laplanche A, Huguier M, et al.  Hepatic arterial infusion of floxuridine in patients with liver metastases from colorectal carcinoma: long-term results of a prospective randomised trial. J Clin Oncol. 1992;10:1112–1118
  18. Allen-Mersh TG, Earlam S, Fordy C, Abrams K, Houghton J. Quality of life and survival with continuous hepatic artery floxuridine infusion for colorectal liver metastases. Lancet. 1994;344:1255–1260
  19. Stein BN, Petrelli NJ, Douglass HO, Driscoll DL, Arcangeli G, Meropol NJ. Age and sex are independent predictors of 5-fluorouracil toxicity. In: Analysis of a large scale phase III trial. 4th edition. Cancer. 75:1995;p. 11–17
  20. Fountzilas G, Gossios K, Zisiadis A, Svarna E, Skarlos D, Pavlidis N. Prognostic variable in patients with advanced colorectal cancer treated with fluorouracil and leucovorin-based chemotherapy. Med Paediatr Oncol. 1996;26:305–317
  21. ACCMP (Advanced Colorectal Cancer Meta-Analysis Project) . Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. J Clin Oncol. 1992;10:896–903
  22. ACCMP (Advanced Colorectal Cancer Meta-Analysis Project) . Meta-analysis of randomised trials testing the biochemical modulation of fluorouracil by methotrexate in metastatic colorectal cancer. J Clin Oncol. 1994;12:960–969
  23. Leichman L, Lenz HJ, Leichman CG, et al.  Quantitation of intratumoral thymidylate synthase expression predicts for resistance for protracted infusion of 5-fluorouracil and weekly leucovorin in disseminated colorectal cancers: preliminary report from an ongoing trial. Eur J Cancer. 1995;31:1306–1310
  24. Kornmann M, Link KH, Lenz HJ, et al.  Thymidylate synthase is a predictor of response and resistance in hepatic artery infusion chemotherapy. Cancer Lett. 1997;118:29–35
  25. Danenberg K, Metzger R, Groshen S, et al.  Thymidylate synthase and thymidine phosphorylase indications of survival for colorectal cancer. In: 4th edition. Proc Am Soc Clin Oncol. 16:1997;p. 914
  26. Johnston PG, Lenz HJ, Leichman CG, et al.  Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumours. Cancer Res. 1995;55(7):1407–1412
  27. Findlay MP, Cunningham D, Morgan G, Clinton S, Harcastle A, Aherne GW. Lack of correlation between thymidylate synthase levels in primary colorectal tumours and subsequent response to chemotherapy. Br J Cancer. 1997;75:903–909
  28. Aschele C, Casazza S, Debernardis D, et al.  Lack of correlation between p53 overexpression and response to Fura-based chemotherapy in advanced colorectal cancer patients. In: 4th edition. Proc Am Soc Clin Oncol. 16:1997;p. 916
  29. Schneider HJ, Sampson SA, Cunningham D, et al.  Bcl-2 expression and response to chemotherapy in colorectal adenocarcinomas. Br J Cancer. 1997;75:427–431
  30. Paradiso A, Rabinovich M, Vallejo C, et al.  p53 and PCNA expression in advanced colorectal cancer: response to chemotherapy and long-term prognosis. Int J Cancer. 1996;69(6):437–441
  31. Benson AB, Catalano PJ, Rao S, et al.  Thymidylate synthase expression as a predictor for response to 5-fluorouracil-based therapy and survival for patients with resected colon or advanced colorectal cancer. In: An ECOG study. 4th edition. Proc Am Soc Clin Oncol. 16:1997;p. 917
  32. Brett MC, Pickard M, Green B, et al.  p53 protein overexpression and response to biomodulated 5-fluorouracil chemotherapy in patients with advanced colorectal cancer. Eur J Surg Oncol. 1996;22:182–185
  33. Kobayashi M, Watanabe H, Ajioka Y, Yoshida M, Hitomi J, Asakura H. Correlation of p53 protein expression with apoptotic incidence in colorectal neoplasia. Virchows Arch. 1995;427(1):27–32
  34. Lennon T, Houghton J, Northover J. What is the value of clinical follow-up for colorectal cancer patients?. In: The experience of the CRC/NIH CEA second-look trial. 4th edition. Nottingham International Colorectal Cancer Symposium. 1995;
  35. Ohlsson B, Breland U, Ekberg H, Graffner H, Tranberg K. Follow-up after curative surgery for colorectal carcinoma. In: Randomised comparison with no follow-up. 4th edition. Dis Colon Rectum. 38:1995;p. 619–626
  36. Makela J, Laitinen S, Kairaluoma M. Five-year follow-up after radical surgery for colorectal cancer. In: Results of a prospective randomised trial. 4th edition. Arch Surg. 130:1995;p. 1062–1067
  37. Seymour MT, Cassidy J, Stenning SP, Duffy AM, Colorectal Cancer Working Party of the UK Medical Research Council . Attitudes and practice in the management of metastatic colorectal cancer in Britain. Clin Oncol. 1997;9:248–251
  38. Medical Research Council (UK) . Trial protocol CR06—chemotherapy choices in advanced colorectal cancer. In: A randomised trial comparing 2 durations and 3 systemic chemotherapy regimens in the palliative treatment of advanced colorectal cancer. Cambridge, UK: MRC Cancer Trials Office; 1997;
  39. Coates A, Gebski V, Bishop JF, et al.  Improving the quality of life during chemotherapy for advanced breast cancer. New Engl J Med. 1987;317:1490–1495
  40. Catimel G  ERASME Group. Comparison of continuous and discontinuous chemotherapy in patients with metastatic breast cancer: final analysis of a phase II randomised study. Ann Oncol. 1992;3(Suppl. 5):79
  41. Bleehen NM, Fayers PM, Girling DJ, Stephens RJ. Controlled trial of twelve versus six courses of chemotherapy in the treatment of small cell lung cancer. Br J Cancer. 1989;59:584–590
  42. Fojo AT, Ueda K, Slamon DJ, Poplack DG, Gottesmann MM, Pastan I. Expression of a multidrug resistance gene in human tumours and tissues. In: 4th edition. Proc Natl Acad Sci USA. 84:1987;p. 265–269
  43. Danenberg PV, Danenberg KD. Effect of 5,10-methylenetetrahydrofolate on the dissociation of fluoro-2′deoxyuridylate from thymdylate synthetase: evidence for an ordered mechanism. Biochemistry. 1978;17:4018–4024
  44. Ingraham HA, Tseng BY, Goulian M. Mechanism for exclusion of 5-fluorouracil from DNA. Cancer Res. 1980;40:998–1001
  45. Chu E, Lai GM, Zinn S, Allegra CJ. Resistance of a human ovarian cancer line to 5-fluorouracil associated with decreased levels of 5-fluorouracil in DNA. Mol Pharmacol. 1990;38:410–417
  46. Chu E, Zinn S, Boarman D, Allegra CJ. Interaction of g interferon and 5-fluorouracil in the H630 human colon carcinoma cell line. Cancer Res. 1990;50:5834–5840
  47. Chu E, Koeller DM, Casey JL, et al.  Autoregulation of human thymidylate synthase messenger RNA translation by thymidylate synthase. In: 4th edition. Proc Natl Acad Sci USA. 88:1991;p. 8977–8981
  48. Moran RG, Keyomarsi K, Patel R. Tumour cell responses to inhibition of thymidylate synthase. Adv Exp Med Biol. 1988;244:71–83
  49. Elias L, Sandoval . Interferon effects upon fluorouracil metabolism by HL-60 cells. Biochem Biophys Res Commun. 1989;163:867–874
  50. Greenhalgh DA, Parish JH. Effects of 5-fluorouracil on cytotoxicity and RNA metabolism in human colonic carcinoma cells. Cancer Chemother Pharmacol. 1989;25:37–44
  51. Maybaum J, Ullman B, Mandel HG, et al.  Regulation of RNA- and DNA-directed actions of 5-fluoropyrimidines in mouse T-lymphoma (S-49) cells. Cancer Res. 1980;40:4209–4215
  52. Drewinko B, Yang L-Y. Cellular basis for the inefficacy of 5FU in human colon carcinoma. Cancer Treat Rep. 1985;69:1391–1398
  53. Lokich JJ, Ahlgren JD, Gullo JJ, Philips JA, Fryer JG. A prospective randomised comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a Mid-Atlantic Oncology Program study. J Clin Oncol. 1989;7:425–432
  54. Hansen RM, Ryan L, Anderson T, et al.  Phase III study of bolus versus infusion fluorouracil with or without cisplatin in advanced colorectal cancer. J Natl Cancer Inst. 1996;88:668–674
  55. Rougier P, Buyse M, Ryan L, et al.  Meta-analysis of all trials comparing intravenous bolus administration to continuous infusion of 5-fluorouracil in patients with advanced colorectal cancer. In: 4th edition. Proc Am Soc Clin Oncol. 16:1997;p. 946
  56. Larsson PA, Carlsson G, Gustavsson B, Graf W, Glimelius B. Different intravenous administration techniques for 5-fluorouracil. In: Pharmacokinetics and pharmacodynamic effects. 4th edition. Acta Oncol. 35:1996;p. 207–212
  57. Levi FA, Zidani R, Vannetzel JM, et al.  Chronomodulated versus fixed-infusion rate delivery of ambulatory chemotherapy with oxaliplatin, fluorouracil, and folinic acid (leucovorin) in patients with colorectal cancer metastases: a randomised multi-institutional trial. J Natl Cancer Inst. 1994;86:1608–1617
  58. Levi F, Zidani R, Misset J. Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer. Lancet. 1997;350:681–686
  59. Greco FA, Figlin R, York M, et al.  Phase III randomised study to compare interferon alfa-2a in combination with fluorouracil versus fluorouracil alone in patients with advanced colorectal cancer. J Clin Oncol. 1996;14:2674–2681
  60. Seymour M, Slevin M, Kerr D, et al.  Randomised trial assessing the addition of inteferon α-2a to fluorouracil and leucovorin in advanced colorectal cancer. J Clin Oncol. 1996;14:2280–2288
  61. Hill M, Norman A, Cunningham D, et al.  Impact of protracted venous infusion fluorouracil with or without interferon alfa-2b on tumor response, survival, and quality of life in advanced colorectal cancer. J Clin Oncol. 1996;13:2317–2323
  62. Hill M, Norman A, Cunningham D, et al.  Royal Marsden phase III trial of fluorouracil with or without interferon alfa-2b in advanced colorectal cancer. J Clin Oncol. 1995;13:1297–1302
  63. Corfu—A Study Group. Phase III randomized study of two fluorouracil combinations with either interferon alfa-2a or leucovorin for advanced colorectal cancer. J Clin Oncol. 1995;13:921–928
  64. Laufman LR, Bukowski RM, Collier MA, et al.  A randomised, double-blind trial of fluorouracil plus placebo versus fluorouracil plus oral leucovorin in patients with metastatic colorectal cancer. J Clin Oncol. 1993;11:1888–1893
  65. Blijham G, Wagener T, Wils J, et al.  Modulation of high-dose infusional fluorouracil by low-dose methotrexate in patients with advanced or metastatic colorectal cancer: final results of a randomised European Organisation for Research and Treatment of Cancer study. J Clin Oncol. 1996;14:2266–2273
  66. Petrelli N, Douglass HO, Herrera L, et al.  The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: a prospective randomised phase III trial. In: Gastrointestinal Tumour Study Group. 4th edition. J Clin Oncol. 7:1989;p. 1419–1426
  67. Poon M, O'Connell MJ, Wieand HS, et al.  Biochemical modulation of fluorouracil with leucovorin: confirmatory evidence of improved therapeutic efficacy in advanced colorectral cancer. J Clin Oncol. 1991;9:1967–1972
  68. Buroker TR, O'Connell MJ, Wieand HS, et al.  Randomised comparison of two schedules of fluorouracil and leucovorin in the treatment of advanced colorectal cancer. J Clin Oncol. 1994;12:14–20
  69. Jager E, Heike M, Bernhard H, et al.  Weekly high-dose leucovorin combined with fluorouracil in advanced colorectal cancer: results of a randomised multicentre trial. In: Study Group of Palliative Treatment of Metastatic Colorectal Cancer Study Protocol 1. 4th edition. J Clin Oncol. 14:1996;p. 2274–2279
  70. Labianca R, Cascinu S, Frontini L, et al.  High versus low dose levo-leucovorin as a modulator of 5-fluorouracil in advanced colorectal cancer: a GISCAD phase III study. In: Italian Group for the study of digestive tract cancer. 4th edition. Ann Oncol. 8:1997;p. 169–174
  71. De Gramont A, Bosset JF, Milan C, et al.  Randomised trial comparing monthly low-dose leucovorin and fluorouracil bolus with bi-monthly high dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French Intergroup study. J Clin Oncol. 1997;15:808–815
  72. Weh HJ, Wilke HJ, Dierlamm J, et al.  Weekly therapy with folinic acid and high dose 5-fluorouracil 24-hour infusion in pretreated patients with metastatic colorectal carcinoma. In: A multicentre study by the Association of Medical Oncology of the German Cancer Society (AIO). 4th edition. Ann Oncol. 5:1994;p. 233–237
  73. Gray R, James R, Mossman J, Stenning S. AXIS—a suitable case for treatment. Br J Cancer. 1991;63:851–855
  74. Stagg RJ, Lewis BJ, Friedman MA, Ignoffo RJ, Hohn DB. Hepatic arterial chemotherapy for colorectal cancer metastatic to liver. Ann Intern Med. 1984;100:736–743
  75. Meta-Analysis Group in Cancer. Reappraisal of hepatic arterial infusion in the treatment of nonresectable liver metastases from colorectal cancer. J Natl Cancer Inst. 1996;88:252–258
  76. Medical Research Council (UK) . Trial protocol CR05—chemotherapy choices in colorectal cancer. In: A randomised trial of intravenous versus intrahepatic arterial 5-FU and leucovorin for colorectal liver metastases. Cambridge, UK: MRC Cancer Trials Office; 1994;
  77. Anttila MI, Sotaniemi EA, Kaiaralcoma MI. Pharmacokinetics of ftorafur after intravenous and oral administration. Cancer Chemother Pharmacol. 1983;10:150–153
  78. Pazdur R, Covington WP, Brown NS, Lassere Y, Diaz-Canton E, Ho DH. Comparative steady state pharmacokinetics of oral UFT versus protracted intravenous 5-fluouroucil. In: 4th edition. Proc Am Soc Clin Oncol. 15:1996;p. 1498
  79. Ota JM, Taguchi T, Kimura K. Report on nationwide pooled data and cohort investigation in UFT phase II study. Cancer Chemother Pharmacol. 1988;22:333–338
  80. Rustum YM, Cao S, Shirasaka T, Taguchi T. A new 5-fluorouracil prodrug, S-1, orally bioavailable with high therapeutic index in model system active in phase II clinical trials. In: 4th edition. Proc Am Soc Clin Oncol. 16:1997;p. 799
  81. Findlay MP, van Cutsem E, Kocha W, et al.  A randomised phase II study of Xeloda (capecitabine) in patients with advanced colorectal cancer. In: 4th edition. Proc Am Soc Clin Oncol. 16:1997;p. 798
  82. Cunningham D, Zalcberg JR, Rath U, et al.  “Tomudex” Colorectal Cancer Study Group  Final results of a randomised trial comparing ‘Tomudex’® (raltitrexed) with 5-fluorouracil plus leucovorin in advanced colorectal cancer. Ann Oncol. 1996;7:961–965
  83. Cripps MC, Burnelf M, Jolivet J, et al.  Phase II study of a multi-targeted antifolate (LY231514) as first-line therapy in patients with locally advanced or metastatic colorectal cancer. Prom Am Soc Clin Oncol. 1997;16:949
  84. Loehrer PJ, Turner S, Kubilis P, et al.  A prospective randomised trial of fluorouracil versus fluorouracil plus cisplatin in the treatment of metastatic colorectal cancer: a Hosier Oncology Group trial. J Clin Oncol. 1988;6:642–648
  85. Kemeny N, Israiel K, Niedzwieckid , et al.  Randomised study of continuous infusion fluorouracil versus fluorouracil plus cisplatin in patients with libitum colorectal cancer. J Clin Oncol. 1990;8:313–318
  86. Lokich JJ, Ahlgren JD, Cantrell , et al.  A prospective randomised comparison of protracted infusional 5-fluorouracil with or without weekly bolus cisplatin in metastatic colorectal carcinoma. In: A Mid-Atlantic Oncology Program study. 4th edition. Cancer. 67:1991;p. 14–19
  87. Scheithauer W, Depish D, Kornek G, et al.  Randomised comparison of fluorouracil and leucovorin therapy versus fluorouracil, leucovorin, and cisplatin therapy in patients with advanced colorectal cancer. Cancer. 1994;73:1562–1568
  88. Becouarn Y, Ychou M, Ducreux M, et al.  Oxaliplatin as firstline chemotherapy in metastatic colorectal cancer patients: preliminary activity-toxicity report. In: 4th edition. Proc Am Soc Clin Oncol. 16:1997;p. 804
  89. Machover D, Diaz-Rubio E, de Gramont A, et al.  Two consecutive phase II studies of oxaliplatin for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines. Ann Oncol. 1996;7:95–98
  90. Pappamichael D, Joel SP, Seymour MT, Bowerbank M, Slevin ML. Pharmacokinetic interaction between 5-fluorouracil and oxaliplatin. In: 4th edition. Proc Am Soc Clin Oncol. 17:1998;p. 777
  91. De Gramont A, Vignoud J, Tournigand C, et al.  Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer. Eur J Cancer. 1997;33:214–219
  92. De Gramont A, Figer A, Seymour MT, Homerin M, Le Ball N, Cassidy J, et al. A randomized trial of leucovorin and 5-fluorouracil with or without oxaliplatin in advanced colorectal cancer. In: 4th edition. Proc Am Soc Clin Oncol. 17:1998;p. 985
  93. Rougier P, Bugat R, Douillard JY, et al.  Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pre-treated with fluorouracil-based chemotherapy. J Clin Oncol. 1997;15:251–260
  94. Cunningham D, Pyrhonen S, James RD, et al.  A Phase III multicentre randomised study of CPT-11 versus supportive care alone in patients with 5FU-resistant metastatic colorectal cancer. In: 4th edition. Proc Am Soc Clin Oncol. 17:1998;p. 1
  95. Van Cursem E, Bajetta E, Niederle N, et al.  A phase III multicentre randomized trial company CPT-II to infusional 5FU regimen in patients with advanced colorectal cancer after 5FU failure. In: 4th edition. Proc Am Soc Clin Oncol. 17:1998;p. 984
  96. Moertel CG. Chemotherapy of gastrointestinal cancer. New Engl J Med. 1978;299:1049–1055
  97. Richards F, Case LD, White DR, et al.  Combination chemotherapy (5-fluorouracil, methyl-CCNU, mitomycin) versus 5-fluorouracil alone for advanced previously untreated colorectal carcinoma. In: A phase III study of the Piedmont Oncology Association. 4th edition. J Clin Oncol. 4:1986;p. 565–570 (4)
  98. Ross P, Norman A, Cunningham D, et al.  A prospective randomised trial of protracted venous infusion 5-fluorouracil with or without mitomycin C in advanced colorectal cancer. Ann Oncol. 1997;8:995–1001
  99. IMPACT—International Multicentre Pooled Analysis of Colon Cancer Trials, Investigators . Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. Lancet. 1995;345:939–944
  100. O'Connell M, Mailliard J, Kahn MJ, et al.  Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer. J Clin Oncol. 1997;15:246–250
  101. Wolmark N, Rockette H, Fisher B, et al.  The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: results from National Surgical Adjuvant Breast and Bowel Project protocol C-03. J Clin Oncol. 1993;11:1879–1887
  102. Primrose JN, Bleiberg H, Daniel F, et al.  Marimastat in recurrent colorectal cancer — exploratory evaluation of biological activity by measurement of carcinoembryonic antigen. Br J Cancer. 1998; in press
  103. Eckhardt SG, Burris HA, Eckhardt JR, et al.  A phase 1 clinical and pharmacokinetic study of the angiogenesis inhibitor tecogalan sodium. Ann Oncol. 1996;7:491–496
  104. Reitmuller G, Schneider-Gadicke E, Schlimok G et al. Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma. Lancet, 343: 1177–1183.
  105. Hoover HC, Brandhorst JS, Peters LC, et al.  Adjuvant active specific immunotherapy for human colorectal cancer: 6.5-year median follow-up of a phase III prospectively randomized trial. J Clin Oncol. 1993;11:385–386
  106. Conry RM, Lobuglio AF, Loechel F, et al.  A carcinoembryonic antigen polynucleotide vaccine for human clinical use. Cancer Gene Ther. 1995;2:33–38
  107. Chang AE, Cameron MJ, Sondak VK, Geiger JD, Vander Woude DL. A phase II trial of interleukin-2 and interferon-alpha in the treatment of metastatic colorectal carcinoma. J Immunother Emphasis Tumour Immunol. 1995;18:253–262
  108. Rosenberg SA, Lotze MT, Yang JC, et al.  Prospective randomized trial of high dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer. J Natl Cancer Inst. 1993;85:622–632
  109. Martin J, Stribbling SM, Poon GK, et al.  Antibody-directed enzyme prodrug therapy: pharmacokinetics and plasma levels of prodrug and drug in a phase I clinical trial. Cancer Chemother Pharmacol. 1997;40:189–201
  110. Bookstein R, Demers W, Gregory R, Maneval D, Park J, Wills K. p53 gene therapy in vivo of hepatocellular and liver metastatic colorectal cancer. Semin Oncol. 1996;23(1):66–77 (review)
  111. Zbar M, Leomine NR, Wadhwa M, Thomas H, Snary D, Kmiot WA. Biological therapy approaches in colorectal cancer. In: Strategies to enhance carcinoembryonic antigen as an immunological target. 4th edition. Br J Cancer. 77:1998;p. 683–693

PII: S0305-7372(98)90078-0

Cancer Treatment Reviews
Volume 24, Issue 2 , Pages 119-131 , April 1998

Article Tools